Anti-IL18 antibodies are available as a potential pharmacological approach as well as recombinant IL18 binding protein but have not yet been investigated for neurodegenerative disease (McKie et al. 2016; Gabay et al. 2018; Mistry et al. 2014). Here, IL18 is linked to neurodegenerative disease.